

AD \_\_\_\_\_

Award Number: W81XWH-07-1-0205

TITLE: New Bone Foundation in a Chronically-Infected Segmental Defect in the Rat Femur Treatment with BMP-2 and Local Antibiotic

PRINCIPAL INVESTIGATOR: David W. Polly, Jr., M.D.

CONTRACTING ORGANIZATION: University of Minnesota  
Minneapolis, MN 55455

REPORT DATE: January 2008

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. <b>PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.</b>					
1. REPORT DATE 01-01-2008		2. REPORT TYPE Annual		3. DATES COVERED 1 Feb 2007 – 31 Dec 2007	
4. TITLE AND SUBTITLE  New Bone Foundation in a Chronically-Infected Segmental Defect in the Rat Femur Treatment with BMP-2 and Local Antibiotic				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-07 -1 0205	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S)  David W. Polly, Jr., M.D. Joan E. Bechtold, Ph.D., William D. Lew  Email: pollydw@umn.edu; edavis@mmrf.org; <a href="mailto:blew@mmrf.org">blew@mmrf.org</a>				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)  University of Minnesota Minneapolis, MN 55455				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT The overall goal of this research was to improve treatment of infected segmental bone loss that occurs in combat injuries. The specific aim of this study was to demonstrate whether human recombinant bone morphogenetic protein-2 (rhBMP-2) and antibiotic delivered locally in a composite carrier, together with administration of systemic antibiotic, can lead to new bone formation in an internally-stabilized segmental defect in a rat femur with a chronic infection from Staphylococcus aureus. It was found that rhBMP-2 maintained its osteoinductive capability despite the presence of chronic infection and colonized hardware, and this property was enhanced by local and systemic antibiotic. No significant new bone was formed unless rhBMP-2 was introduced. A composite collagen sponge/ceramic-collagen matrix carrier containing 200 µg of rhBMP-2 (sponge) and 100 mg of Cefazolin (matrix) was applied to surgically debrided defects, together with 4 weeks of systemic administration of the antibiotic Ceftriaxone. Despite the chronic infection, this treatment induced a substantial amount of newly mineralized callus that connected the ends of the defect 8 weeks after debridement such that there was no significant difference between the torsional failure strength of these treated defects and the intact contralateral femurs.					
15. SUBJECT TERMS segmental defect, chronic infection, Staphylococcus aureus, bone morphogenetic protein, antibiotic, osteomyelitis, BMP-2, rat model					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
U	U	U	UU	17	19b. TELEPHONE NUMBER (include area code)

## Table of Contents

	<u>Page</u>
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	14
Reportable Outcomes.....	15
Conclusion.....	15
References.....	16
Personnel Receiving Pay From the Grant.....	16
Appendices.....	17
Supporting Data.....	17

# Introduction

The majority of the combat casualties that occur in Operations Iraqi Freedom and Enduring Freedom are a result of high-energy blast or high-velocity projectile mechanisms, and commonly present with a significant segmental bone defect, massive soft tissue disruption and loss, and substantial contamination with bacteria. The goal of this research was to improve the treatment of infected segmental bone loss by using currently available off-the-shelf biologics and antibiotics. Specifically, the aim of this study was to determine whether recombinant human bone morphogenetic protein-2 (rhBMP-2) and antibiotic delivered locally from a composite carrier, in combination with a second antibiotic delivered systemically, could lead to new bone formation in an internally-stabilized rat femoral segmental defect with a chronic infection from *Staphylococcus aureus*. It is hypothesized that (i) chronically-infected defects treated with debridement and rhBMP-2 would form significantly more and stronger new bone than debrided defects without rhBMP-2, (ii) defects treated with debridement, rhBMP-2 and local administration of a high dose of antibiotic would form significantly more and stronger new bone than debrided defects treated with rhBMP-2 alone, and (iii) defects treated with debridement, rhBMP-2, local administration of a high dose of antibiotic, and systemic administration of a second antibiotic, would form significantly more and stronger new bone than debrided defects treated with rhBMP-2 and local antibiotic alone.

# Body

We have completed the primary and debridement surgeries on all 2, 4, 8 and 12-week animals in **Table 1** below. A 6 mm segmental defect was surgically created and stabilized with a polyacetyl plate and 6 Kirschner wires in the left femur in each animal.<sup>1-4</sup> All defects were contaminated with 10<sup>4</sup> colony-

**Table 1.** Experimental design

Treatment			Number of Animals Studied				
rhBMP-2 Dose	Local Antibiotic (Cefazolin)	Systemic Antibiotic (Ceftriaxone)	Total	Time From Debridement			
				2 wk*§	4 wk*§	8 wk*§	12 wk*§
200 µg	yes	yes	72	12†#	20‡#	20‡#	20‡#
		no	72	12†#	20‡#	20‡#	20‡#
20 µg	yes	yes	56	8†	16‡	16‡	16‡
		no	56	8†	16‡	16‡	16‡
0 µg	yes	no	32	8	8	8	8
200 µg	no	no	32	8†	8†	8†	8†
0 µg	no	no	32	8	8	8	8

\* radiographic grading of bony lysis: n = 8 animals for each of the 6 treatments at the indicated time-points  
† micro-computed tomography: n = 8 animals at the indicated rhBMP-2 treatments/time-points  
§ descriptive undecalcified histology: n = 4 animals randomly chosen from among the 8 animals used for the above imaging assessments for each of the 7 treatment at the indicated time-points  
‡ torsional failure testing: n = 8 additional animals at the indicated rhBMP-2 treatments/time-points  
# quantitative bacteriology: n = 4 additional animals at the indicated rhBMP-2 treatments/time-points


forming units (CFUs) of *Staphylococcus aureus*. The animals were allowed to recover for 2 weeks during which time the initial contamination progressed to a chronic infection. All defects were then thoroughly debrided under sterile conditions, and treated with a composite type 1 bovine collagen sponge/ceramic-collagen matrix carrier containing 0, 20 or 200 µg of rhBMP-2 in sterile water (used to wet the sponge), with and without a 100 mg dose of Cefazolin dissolved in sterile water (used to wet the matrix). The sponge was wrapped around the matrix and packed into the defect. In half of the animals receiving rhBMP-2 and local Cefazolin, a systemic antibiotic (Ceftriaxone) was also administered for 28 days (intramuscular injection, 50 mg/kg once per day).

Assessments and findings for the 2, 4 and 8-week animals are summarized below. The 12-week animals have yet to be euthanized and their assessments initiated. We have been granted a no-cost extension to complete this work.


### Micro-Computed Tomography

Micro-CT scans have been completed for the 2, 4 and 8-week animals. Scans for the 12-week group will be preformed after the animals are euthanized during our no-cost extension period. Micro-CT results revealed that BMP maintained its osteoinductive capability despite the presence of chronic infection and colonized hardware (**Figures 1 and 2**). No substantial callus formed in the chronically infected defects without a sufficiently high dose of BMP.

**Figure 1.** 3-d rendering (left) and sectional view (right) of representative micro-CT scan of defect treated with 200 µg of rhBMP-2 with both local and systemic antibiotic at 4 weeks; note the segment of ceramic collagen matrix remaining in the defect



**Figure 2.** 3-d rendering (left) and sectional view (right) of representative micro-CT scan of defect treated with 20 µg of rhBMP-2 with both local and systemic antibiotic at 4 weeks



The volume, surface area, surface area-to-volume ratio and average grayscale of the total amount of newly mineralized callus formed within the defect and bridging the outside of the defect at 2, 4 and 8 weeks, as well as the volume of the ceramic collagen matrix carrier remaining in the defect and percentage of new callus formed within the defect, are presented in **Table 2**.

**Table 2.** Complete set of micro-CT data\*

CT Parameters	Treatments				
	20+L-S	20+L+S	200-L-S	200+L-S	200+L+S
Total Volume (mm <sup>3</sup> )					
2 Week	21 (16)‡	25 (13)‡	17 (17)‡	34 (22)	46 (20)§
4 Week	43 (54)	19 (19)	23 (16)	43 (41)	70 (28)
8 Week	43 (32)	57 (33)	48 (50)	73 (34)	92 (29)
12 Week†	-	-	-	-	-
Matrix Volume (mm <sup>3</sup> )					
2 Week	18 (7)	13 (5)	13 (11)	13 (8)	21 (6)
4 Week	12 (4)	18 (10)	10 (10)	12 (6)	20 (5)
8 Week	9 (5)ξ	17 (12)	9 (6)	12 (5)	18 (6)
12 Week†	-	-	-	-	-
Total Surface Area (mm <sup>2</sup> )					
2 Week	598 (556)‡	584 (203)‡	422 (398)‡	1046 (723)	1324 (602)
4 Week	936 (1007)	478 (573)	418 (299)‡	1183 (1089)	1909 (879)
8 Week	619 (346)‡	945 (560)‡	764 (757)‡	1313 (925)	1904 (763)
12 week†	-	-	-	-	-
Surface Area/Volume Ratio					
2 Week	26 (7)	27 (8)	31 (14)	29 (7)	29 (5)
4 Week	26 (4)	22 (5)	19 (4)	29 (6)	27 (4)
8 Week	17 (5)	16 (3)	17 (3)	17 (4)	20 (3)
12 week†	-	-	-	-	-
Average Grayscale					
2 Week	1783 (95)§	1827 (124)§	1790 (90)§**	1793 (191)§	1710 (78)§
4 Week	1848 (91)§	2051 (166)¶	2006 (148)¶	1895 (156)§	1735 (64)§
8 Week	2151 (157)	2175 (299)	2090 (239)	2116 (214)	1990 (141)
12 week†	-	-	-	-	-
% New Callus Within Defect					
2 Week	52 (24)	54 (12)	35 (18)	25 (14)	28 (14.)
4 Week	63 (31)	70 (26)	61 (17)	45 (18)	37 (18)
8 Week	59 (18)	54 (18)	48 (22)	31 (11)	32 (11)
12 Week†	-	-	-	-	-

\* Data shown as mean (standard deviation); 20 or 200 µg rhBMP-2, L = Local antibiotic, S = Systemic antibiotic

† These data will be filled in once the 12-week animals are euthanized under our no-cost extension

‡ Significantly less than treatment with 200+L+S at same time point (p<0.045, one-way analysis of variance)

§ Significantly less than same treatment at 8 weeks (p<0.045, one-way analysis of variance)

ξ Significantly less than same treatment at 2 weeks (p=0.026, one-way analysis of variance)


¶ Significantly greater than 200+L+S at the same time point (p<0.009, one-way analysis of variance)

\*\* Significantly less than same treatment at 4 weeks (p=0.032, one-way analysis of variance)

The greatest amount of new bone formation occurred with 200  $\mu$ g of rhBMP-2 augmented with both local and systemic antibiotic (**Figure 3, Table 2**). The total volume and total surface area with the 200  $\mu$ g dose of rhBMP-2 with local and systemic antibiotic were greater than with 200  $\mu$ g of rhBMP-2 with systemic antibiotic alone, and 200  $\mu$ g of rhBMP-2 with no antibiotic. The mean total volume and total surface area were greater with 200  $\mu$ g of rhBMP-2 than with 20  $\mu$ g (**Figure 3, Table 2**). There was a clear dose response relationship between rhBMP-2 and bone formation, and application of local and systemic antibiotic affected this relationship in a positive way. The mean total volume, total surface area and average grayscale of newly formed callus increased with time from debridement for all treatment groups except for the total surface area for the 20  $\mu$ g rhBMP-2 group with local antibiotic only (**Figure 3, Table 2**). The ceramic collagen matrix carrier for the delivery of local antibiotic was not resorbed by 8 weeks after debridement (**Figures 1 and 2, Table 2**). Approximately half of the newly mineralized callus formed within the volume of the original defect (**Table 2**).

**Figure 3.** Total volume of newly mineralized callus:

20 or 200  $\mu$ g rhBMP-2, L = Local antibiotic, S = Systemic antibiotic



\*Significantly less than 200+L+S ( $p < 0.045$ )


†8 weeks significantly greater than 2 weeks ( $p = 0.003$ )

### Torsional Failure Testing

Treated and intact femurs were loaded to failure in torsion in a materials test machine (**Figure 4**). Torque versus angular displacement data were recorded and used to compute torque to failure, energy absorbed to failure, and torsional stiffness of the newly mineralized callus.

**Figure 4.** Illustration of failure testing of a segmental defect with callus formation.

A section of the fixation plate was removed so as to not influence failure testing.



The 4- and 8-week torsional failure testing data are presented in **Table 3**. Failure testing for the 12-week group will be performed after the animals are euthanized during our no-cost extension period.

**Table 3.** Complete set of torsional failure test data\*

Mechanical Parameters	Treatments			
	20+L-S	20+L+S	200+L-S	200+L+S
Maximum Torque (Nm)				
4 Week				
Treatment	-	-	0.149 (0.029)	0.162 (0.087)
Intact contralateral	-	-	-	-
8 Week				
Treatment	0.094 (0.135)‡§	0.045 (0.086)‡§ξ	0.243 (0.181)‡	0.376 (0.157)
Intact contralateral	0.371 (0.095)	0.459 (0.102)	0.547 (0.170)	0.478 (0.099)
12 Week†				
Treatment	-	-	-	-
Intact contralateral	-	-	-	-
Energy to Failure (Nm-deg)				
4 Week				
Treatment	-	-	0.825 (0.086)	1.543 (1.136)
Intact contralateral	-	-	-	-
8 Week				
Treatment	0.496 (0.654)§	0.206 (0.261)‡§	1.031 (0.862)‡	1.716 (0.756)‡
Intact contralateral	1.453 (0.703)§ξ	2.531 (1.917)	4.046 (1.337)	3.351 (1.348)
12 Week†				
Treatment	-	-	-	-
Intact contralateral	-	-	-	-
Linear Stiffness (Nm/deg)				
4 Week				
Treatment	-	-	0.0196 (0.0000391)	0.0254 (0.0161)
Intact contralateral	-	-	-	-
8 Week				
Treatment	0.0212 (0.0367)‡§	0.0118 (0.0277)‡§	0.0395 (0.0336)	0.0692 (0.0359)
Intact contralateral	0.0652 (0.0111)	0.0699 (0.0224)	0.0560 (0.0158)	0.0435 (0.0164)
12 Week†				
Treatment	-	-	-	-
Intact contralateral	-	-	-	-

\* Data shown as mean (standard deviation); 20 or 200 µg rhBMP-2, L = Local antibiotic, S = Systemic antibiotic

† These data will be filled in once the 12-week animals are euthanized under our no-cost extension

‡ Significantly less than intact contralateral femur ( $p < 0.017$ , paired Student's t-test)

§ Significantly less than with 200+L+S ( $p < 0.030$ , one-way analysis of variance)

ξ Significantly less than with 200+L-S ( $p < 0.032$ , one-way analysis of variance)


Many of the specimens that were to be mechanically tested exhibited new bone formation in and around the defect as shown by the micro-CT data, but this new bone did not sufficiently unite the ends of the defect so as to resist the applied torque. This was especially evident in the 4-week animals. The mean failure strength of the 8-week treatment group with 200 µg of rhBMP-2 in combination with local and systemic antibiotic was not significantly different than the mean strength of the respective intact contralateral femurs (**Figure 5**,  $p > 0.05$ , paired Student's t-test). On the other hand, the mean failure strengths of defects in the other three treatment groups (20 µg of rhBMP-2 with local antibiotic



with/without systemic antibiotic, and 200  $\mu$ g rhBMP-2 with local antibiotic only) were significantly less than their intact counterparts at 8 weeks ( $p < 0.001$ , paired Student's t-test).

The group with 200  $\mu$ g rhBMP-2 in combination with local and systemic antibiotic exhibited the highest mean mechanical strength of any of the treatments at 8 weeks (**Table 3**). The mean torsional failure strength in this treatment group was significantly greater than the two 20  $\mu$ g rhBMP-2 groups ( $p < 0.003$ , one-way analysis of variance).

**Figure 5.** Failure torque (mean, standard deviation) at 8 weeks as a function of rhBMP-2 dose + antibiotic therapy: 20 or 200  $\mu$ g rhBMP-2, L = Local antibiotic, S = Systemic antibiotic




\*Significantly less than intact contralateral femur ( $p < 0.005$ )


### Bony Lysis

Bone damage in infected segmental defects initially presents on high resolution radiographs as cortical osteolysis adjacent to the Kirschner wires as they cross the cortical bone (**Figures 6 and 7**).<sup>3,4</sup> A simple count of the number of sites of lysis (6 Kirschner wires crossing cortical bone twice, or 12 possible sites) has been shown to correlate with the torsional stiffness of the defect fixation.<sup>1</sup>

**Figure 6.** Illustration of osteolysis in segmental defect model with chronic infection



**Figure 7.** Representative radiograph showing osteolysis in the segmental defect model



Faxitron radiographs were obtained for the 2, 4 and 8-week animals. The numbers of sites of osteolysis are summarized in **Table 4** below. At least some level of osteolysis occurred over the study period regardless of treatment. This suggests that the infection was truly chronic and could likely not be completely eliminated without removal of the fixation implant. There was a large amount of variation in the occurrence of bony lysis among the specimens which reflects the inherent variability of infection whether in animal models or clinically. The median number of sites of lysis was lowest when the infected defects were treated with 200 µg of BMP-2, together with both local and systemic antibiotic. Addition of systemic antibiotic to the local administration of antibiotic reduced the occurrence of lysis with both 20 and 200 µg of rhBMP-2, although this was not statistically significant. The median number of sites of lysis was lower with 200 µg of rhBMP-2 than with 20 µg, for a given antibiotic treatment (local ± systemic), which suggests the possibility that rhBMP-2 may somehow be involved with modulating the infective process.

**Table 4.** Median number of sites of bony lysis from high resolution radiographs

Treatment			Number of Sites of Lysis*			
rhBMP-2 Dose	Local Antibiotic (Cefazolin)	Systemic Antibiotic (Ceftriaxone)	Time From Debridement			
			2 wk	4 wk	8 wk	12 wk†
200 µg	yes	yes	2 (3)	2 (2.25)	0 (1)	-
		no	4 (5.5)‡	2.5 (2)	1.5 (2)	-
20 µg	yes	yes	3.5 (3)	6 (5.5)	3 (3)	-
		no	3 (4.5)	9.5 (6.5)§	6 (1.75)§	-
0 µg	yes	no	8 (4.5)	6 (6.5)	6 (1.5)§¶	-
200 µg	no	no	5 (5)	5 (5)	5 (3.5)§¶	-
0 µg	no	no	5 (2.25)	6 (5)	5 (0)§	-

\* Data shown as median (interquartile range)  
† These data will be filled in once the 12-week animals are euthanized under our no-cost extension  
‡ Significantly greater than same treatment at 8 weeks (p<0.05, Kruskal-Wallis One Way Analysis of Variance on Ranks)  
§ Significantly greater than 200 µg + local antibiotic + systemic antibiotic at same time point (p<0.05, Kruskal-Wallis One Way Analysis of Variance on Ranks)  
¶ Significantly greater than 200 µg + local antibiotic - systemic antibiotic at same time point (p<0.05, Kruskal-Wallis One Way Analysis of Variance on Ranks)

## Qualitative Bacteriology

The defects in all animals became infected by 2 weeks after contamination with 10<sup>4</sup> CFUs of *Staphylococcus aureus*, except for three 8-week animals (**Table 5**). These animals were replaced by three others whose defects did become infected by 2 weeks after contamination. The majority of the cultures from infected defects revealed moderate to many CFUs of *S. aureus*, and occasionally, only a few CFUs were evident, although the defect was still infected.

**Table 5.** Qualitative bacteriology at time of *debridement*

Culture Results	Treatment						
	0-S-L	200-S-L	0+L-S	20+L-S	20+L+S	200+L-S	200+L+S
2 Week Animals							
No growth							
Rare							
Few						1	
Moderate	3	2	3	3	2	4	6
Many	5	5	1		3	4	4
Contaminated*			3	5	3		
4 Week Animals							
No growth							
Rare							
Few		2					
Moderate	2	4	1	1	2	2	6
Many	5	1	6	12	11	17	13
Contaminated*		1	1	3	3	1	1
8 Week Animals							
No growth							3
Rare							
Few	1			2		1	4
Moderate	5	4	6	6	7	7	4
Many	2	4	2	7	9	12	10
Contaminated*							
12 Week Animals†							
No growth	-	-	-	-	-	-	-
Rare	-	-	-	-	-	-	-
Few	-	-	-	-	-	-	-
Moderate	-	-	-	-	-	-	-
Many	-	-	-	-	-	-	-
Contaminated*	-	-	-	-	-	-	-

20 or 200 µg rhBMP-2, L = Local antibiotic, S = Systemic antibiotic

\* Contamination with another type of bacteria in addition to *Staphylococcus aureus*

† These data will be filled in once the 12-week animals are euthanized under our no-cost extension

Qualitative cultures at the time of euthanization revealed continued bacterial growth in 71% of the defects in the 200 µg rhBMP-2 + local antibiotic group (**Table 6**). Addition of systemic antibiotic therapy to this treatment group decreased the number of defects with bacterial growth at euthanization by half (39%). This reduction in the occurrence of chronic infection from administration of both local and systemic antibiotic was not evident in the 20 µg rhBMP-2 groups. The remaining 3 treatment groups exhibited bacterial growth in 100% of the defects. Thus, qualitative cultures revealed that the chronic infection remained in evidence throughout the study period in the majority of defects, and that administration of both local and systemic antibiotic therapy with 200 µg rhBMP-2 was essential for decreasing the number of defects with infection. These data also reflect the inherent variability with infection and suggest the possibility that the presence of rhBMP-2 itself may have somehow played a role in modulating the infection as evidenced by the different effects in the cultures with the 20 and 200 µg rhBMP-2 groups for a given antibiotic treatment (local ± systemic).

**Table 6.** Qualitative bacteriology at time of *euthanasia*

Culture Results	Treatment						
	0-S-L	200-S-L	0+L-S	20+L-S	20+L+S	200+L-S	200+L+S
2 Week Animals							
No growth					1		8
Rare			1	1	1		2
Few	1		3	3	3	5	
Moderate	5	3		1		2	
Many	2	2				1	
Contaminated*		2	3	2	3	1	
4 Week Animals							
No growth				3	1	3	7
Rare	1		3	4	3	7	5
Few	1	1	2	2	2	6	5
Moderate	3	2	2	3	1	2	2
Many	2	2		2		1	
Contaminated*		3	1	1	8	1	1
8 Week Animals							
No growth				7	5	11	16
Rare	1			3	4	2	3
Few	2	5	3		5	3	2
Moderate	3		5	2	2	3	
Many	2	1		3			
Contaminated*		2				1	
12 Week Animals†							
No growth	-	-	-	-	-	-	-
Rare	-	-	-	-	-	-	-
Few	-	-	-	-	-	-	-
Moderate	-	-	-	-	-	-	-
Many	-	-	-	-	-	-	-
Contaminated*	-	-	-	-	-	-	-

20 or 200 µg rhBMP-2, L = Local antibiotic, S = Systemic antibiotic

\* Contamination with another type of bacteria in addition to *Staphylococcus aureus*

† These data will be filled in once the 12-week animals are euthanized under our no-cost extension

## Quantitative Bacteriology

*S. aureus* was recovered from the femurs with an infected defect even though they were treated with local and systemic antibiotics, as shown in **Table 7**. Treatment of infected defects with 200 µg BMP-2 with both local and systemic antibiotics led to numbers of recovered bacteria that were 4 logs less (at the same level as the contaminating inoculum) than with treatment with 200 µg rhBMP-2 with local antibiotic alone. As was also observed with the qualitative bacteriology, both systemic and local antibiotics were required to substantially impact the chronic infection. Statistical analysis was not performed on these data because there were only 4 samples per group. The intent of these measurements was to simply monitor the progression and magnitude of the infection in a few animals.

**Table 7.** Bacterial census measurements (mean log<sub>10</sub> CFUs per gram of bone)

Treatment	Time from debridement (wks)		
	4	8	12†
200 µg BMP-2 + L	7.88	8.24	-
200 µg BMP-2 + L + S	6.94	3.94	-


L = Local antibiotic, S = Systemic antibiotic

† These data will be filled in once the 12-week animals are euthanized under our no-cost extension

### Undecalcified Histology

Histology of the 2-week and 4-week groups has been completed (**Figure 8**). The histological sections from the 8-week animals are currently being processed and will be completed and analyzed during our no-cost extension period. The histology of the 12-week animals, who have yet to be euthanized, will also be completed during the no-cost extension period.

**Figure 8.** Representative undecalcified sections at 4 weeks




200 µg BMP-2 + local + systemic abx



200 µg BMP-2 + local abx



20 µg BMP-2 + local + systemic abx



20 µg BMP-2 + local abx

The histology findings are summarized in **Table 8**. The greatest amount of new bone formation at 4 weeks occurred with 200 µg of rhBMP-2 augmented with both local and systemic antibiotic.

**Table 8.** Summary of histological findings:  
0, 20 or 200 µg rhBMP-2, L = Local antibiotic, S = Systemic antibiotic

<b>Treatment Group</b>	<b>Description of Histology</b>
<b>2 Week Group</b>	
0-L-S	No new bone formation
0+L-S	No new bone formation
20+L-S	There is scant new bone formation admixed within the matrix carrier surrounded by collagen fibers
200-L-S	No new bone formation
200+L-S	There is scant new bone formation admixed within the matrix carrier surrounded by collagen fibers
20+L+S	There is scant new bone formation admixed within the matrix carrier surrounded by collagen fibers
200+L+S	There is minimal to moderate new bone formation in and around the matrix carrier
<b>4 Week Group</b>	
0-L-S	No new bone formation
0+L-S	No new bone formation
20+L-S	There is minimal new bone formation admixed within the matrix carrier surrounded by collagen fibers
200-L-S	No new bone formation
200+L-S	Minimal new bone formation can be seen within and around the matrix carrier surrounded by collagen fibers.
20+L+S	There is scant new bone formation within the matrix carrier surrounded by collagen fibers
200+L+S	There is moderate new bone formation in and around the matrix carrier with more organized creeping substitution

## Future Work

Primary and debridement surgeries for all study animals have been completed. Assessments for the 2, 4 and 8-week animals have been completed with the findings reported above. The 12-week animals have yet to be euthanized and their assessments initiated. We have been granted a no-cost extension to complete this work.

## Key Research Accomplishments

- Using an animal model with an internally-stabilized segmental defect in the rat femur with a chronic infection from *Staphylococcus aureus*, we learned that ...
  - ▶ Debridement and use of commercially-available off-the-shelf biologics and antibiotics led to formation of newly mineralized callus in spite of retention of the colonized hardware
  - ▶ Recombinant human bone morphogenetic protein-2 with its absorbable collagen sponge carrier maintained its osteoinductive capability despite the presence of chronic infection and colonized hardware. No substantial callus formed in the chronically infected defects without a sufficiently high dose of rhBMP-2.

- ▶ The bone-forming capability of rhBMP-2 in the presence of chronic infection was enhanced by antibiotic therapy. More newly mineralized callus formed with rhBMP-2 and antibiotic introduced local to the defect, compared to defects with rhBMP-2 without local antibiotic. The greatest amount of newly mineralized callus was induced with rhBMP-2 augmented with both local and systemic antibiotic.
- ▶ There was a clear dose response relationship between rhBMP-2 and bone formation, and application of local and systemic antibiotic affected this relationship in a positive way. More newly mineralized callus formed with the higher dose of rhBMP-2 (200 µg) than the lower dose (20 µg). The greatest amount of new bone formation occurred with 200 µg of rhBMP-2 augmented with both local and systemic antibiotic.
- ▶ The strength of the newly mineralized callus formed within and bridging the defect with the high dose of rhBMP-2 in combination with local and systemic antibiotic approached the strength of the intact contralateral femurs. The mechanical strength of all other treatment groups was significantly less than the respective intact contralateral femurs.

## Reportable Outcomes

- Animal model of an internally-stabilized segmental defect in the rat femur with a chronic infection from *Staphylococcus aureus* in which debridement and use of commercially-available off-the-shelf biologics (bone morphogenetic protein-2, absorbable collagen sponge (ACS), ceramic collagen matrix (MasterGraft Matrix)) and antibiotics lead to formation of newly mineralized callus in spite of retention of the colonized hardware
- Manuscripts, abstracts and presentations will be forthcoming as the project is finished during the grant extension period.

## Conclusions

The treatment of an infection at the site of a fracture often necessitates removal of internal fixation. However, internal fixation is needed for fracture stability. This study presents an intervention that may accelerate fracture-healing in the presence of chronic infection and colonized hardware, thereby permitting earlier removal of the hardware and more timely and effective treatment of the infection.

The results of this study demonstrated that rhBMP-2 maintained its osteoinductive capability despite the presence of chronic infection and colonized hardware, and this property was enhanced by local and systemic antibiotic. No significant new bone was formed unless rhBMP-2 was introduced. A composite type 1 bovine collagen sponge/ceramic-collagen matrix carrier containing 200 µg of rhBMP-2 in sterile water (used to wet the sponge) and 100 mg of Cefazolin dissolved in sterile water (used to wet the matrix) was applied to surgically debrided defects, together with 4 weeks of systemic administration of the antibiotic Ceftriaxone. This treatment induced a substantial amount of newly mineralized callus that connected the ends of the defect at 8 weeks after debridement such that there was no significant difference between the torsional failure strength of these treated defects and the intact contralateral femurs.

There was also a clear dose response relationship between rhBMP-2 and bone formation, and application of local and systemic antibiotic affected this relationship in a positive way. More new bone was formed when both systemic and local antibiotic were administered, compared to when local antibiotic was introduced alone. The lower 20 µg dose of rhBMP-2 also led to the formation of newly mineralized callus, particularly when local and systemic antibiotics were administered, but the amount of new bone was less than with the higher 200 µg dose of rhBMP-2. Although newly formed callus was induced in the 20 µg rhBMP-2 defects, this new bone and surrounding inflammatory fibrous tissue did not sufficiently unite the ends of the defects to resist the torque applied with mechanical testing. It is clear from this experiment that the combination of both local and systemic antibiotic and high dose rhBMP-2 had the greatest effect achieving clinical success of bridging bone across the segmental defect - the desired clinical state. There is likely an optimal dose of rhBMP-2 that attains some threshold for adequate stimulation of bone formation in the presence of chronic infection, but this remains to be determined. The molecular and genetic mechanisms involved in the interaction of rhBMP-2, antibiotic and infection are unknown at this point, and should be the subject of future work.

The logical next steps for this work are to assess the efficacy of rhBMP-2 with local and systemic antibiotic in a polymicrobial chronic infection model in the rat, more closely simulating combat injuries, and then develop a similar chronic infection model in a large animal like a goat, which would more closely approximate the human condition.

## References

1. Chen X, Tsukayama DT, Kidder LS, Bourgeault CA, Schmidt AH, Lew WD: Characterization of a Chronic Infection in an Internally Stabilized Segmental Defect in the Rat Femur. *Journal of Orthopaedic Research*, Vol. 23, No. 4, pp. 816-823, 2005.
2. Chen X, Kidder LS, Lew WD: Osteogenic Protein-1 Induced Bone Formation in an Infected Segmental Defect in the Rat Femur. *Journal of Orthopaedic Research*, Vol. 20, No. 1, pp. 142-150, 2002.
3. Chen X, Schmidt AH, Tsukayama DT, Bourgeault CA, Lew WD: Recombinant Human Osteogenic Protein-1 Induces Bone Formation in a Chronically Infected, Internally Stabilized Segmental Defect in the Rat Femur. *Journal of Bone and Joint Surgery [Am]*, Vol. 88, No. 7, pp. 1510-1523, 2006.
4. Chen X, Schmidt AH, Mahjouri S, Polly Jr DW, Lew MD: Union of a Chronically Infected Internally Stabilized Segmental Defect in the Rat Femur after Debridement and Application of rhBMP-2 and Systemic Antibiotic. *Journal of Orthopaedic Trauma*, Vol. 21, No. 10, pp. 693-700, 2007.

## Personnel Receiving Pay From the Grant

David W. Polly Jr, MD: Principal Investigator  
Charles Ledonio, MD: Animal surgeon  
Joan E. Bechtold, PhD: Co-Investigator  
Dean T. Tsukayama, MD: Co-Investigator  
William D. Lew, MS: Investigator  
Barbara W. Wicklund, BS: Bacteriologist  
Brooke Sommer: Animal care technician



**Appendices**    No entries

**Supporting Data**    All supporting data is embedded in the body of the report